Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial

A Correction to this article was published on 22 January 2020

Abstract

This study aimed to appraise the effectiveness and tolerability of lidocaine 5% spray in the treatment of patients with premature ejaculation (PE). The current study has been designed as a randomized single-blind placebo-controlled clinical trial. It was done on 150 lifelong PE patients with normal erection. They were randomized evenly categorized into two treatment groups. Group 1 (n = 75); was given on demand lidocaine 5% spray for 8 weeks. Group 2 (n = 75); was given placebo in the form on demand alcohol spray for 8 weeks. All medications were applied on the glans penis for 10–20 min, and then cleaned before planned sexual intercourse. Patients were evaluated with the Arabic Index of Premature Ejaculation (AIPE) scores, intravaginal ejaculatory latency times (IELTs), and frequency of sexual intercourse before and after treatments. The mean values of the AIPE scores, IELTs, and sexual intercourse frequency in the lidocaine 5% spray group were statistically significant increased than the group of placebo after treatment (P value 0.0001). The present study deduced that local use of lidocaine 5% spray on glans penis 10–20 min prior to sexual intercourse could significantly improve PE patients, with tolerated local adverse effects.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities and proessional help-seeking. Eur Urol. 2007;51:816–24.

    Article  Google Scholar 

  2. 2.

    Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation. Sex Med. 2014;2:41–59.

    Article  Google Scholar 

  3. 3.

    El-Hamd MA, Saleh R, Majzoub A. Premature ejaculation: an update on definition and pathophysiology. Asian J Androl. 2019;21:425–32.

    Article  Google Scholar 

  4. 4.

    Waldinger MD. Recent advances in the classification, neurobiology and treatment of premature ejaculation. Adv Psychosom Med. 2008;29:50–69.

    Article  Google Scholar 

  5. 5.

    Schapiro B. Premature ejaculation, a review of 1130 cases. J Urol. 1943;50:374–9.

    Article  Google Scholar 

  6. 6.

    Guo L, Liu Y, Wang X, Yuan M, Yu Y, Zhang X, et al. Significance of penile hypersensitivity in premature ejaculation. Sci Rep. 2017;7:10441.

    Article  Google Scholar 

  7. 7.

    Jern P, Santtila P, Johansson A, Varjonen M, Witting K, von derPahlen B, et al. Evidence for a genetic etiology to ejaculatory dysfunction. Int J Impot Res. 2009;21:62–7.

    CAS  Article  Google Scholar 

  8. 8.

    Waldinger M, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998;92:111–8.

    CAS  Article  Google Scholar 

  9. 9.

    Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. JCEM. 2005;90:6472–9.

    CAS  Article  Google Scholar 

  10. 10.

    Shamloul R, el-Nashaar A. Chronic prostatitis in premature ejaculation: a cohort study in 153 men. J Sex Med. 2006;3:150–4.

    Article  Google Scholar 

  11. 11.

    Jannini EA, Lombardo F, Lenzi A. Correlation between ejaculatory and erectile dysfunction. Int J Androl. 2005;28:40–5.

    Article  Google Scholar 

  12. 12.

    Clèment GiulianoF. Pharmacology for the treatment of premature ejaculation. Pharm Rev. 2012;64:621–44.

    Article  Google Scholar 

  13. 13.

    Wyllie MG, Hellstrom WJ. The link between penile hypersensitivity and premature ejaculation. BJU Int. 2011;107:452–7.

    Article  Google Scholar 

  14. 14.

    Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine lidocaine cream in premature ejaculation. Andrologia. 2002;34:356–9.

    CAS  Article  Google Scholar 

  15. 15.

    Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo controlled study. BJU Int. 2004;93:1018–21.

    CAS  Article  Google Scholar 

  16. 16.

    Henry R, Morales A, Wyllie MG. TEMPE: topical eutectic-like mixture for premature ejaculation. Expert Opin Drug Deliv. 2008;5:251–61.

    CAS  Article  Google Scholar 

  17. 17.

    Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo controlled study. BJU Int. 2009;103:940–9.

    CAS  Article  Google Scholar 

  18. 18.

    Shamloul R, Ghanem H, Abou-zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res. 2004;16:452–5.

    CAS  Article  Google Scholar 

  19. 19.

    Arafa M, Shamloul R. Development and evaluation of the Arabic Index of Premature Ejaculation (AIPE). J Sex Med. 2007;4:1750–56.

    Article  Google Scholar 

  20. 20.

    Waldinger MD, Olivier B. Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr Opin Investig Drugs. 2004;5:743–7.

    CAS  PubMed  Google Scholar 

  21. 21.

    Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJG, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two doubleblind, randomised controlled trials. Lancet. 2006;368:929–37.

    CAS  Article  Google Scholar 

  22. 22.

    Butcher MJ, Zubert T, Christiansen K, Carranza A, Pawlicki P, Seibel S. Topical agents for premature ejaculation: a review. Sex Med Rev. 2019. https://doi.org/10.1016/j.sxmr.

  23. 23.

    Dinsmore WW, Hackett G, Goldmeier D. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int. 2006;99:369–75.

    Article  Google Scholar 

  24. 24.

    Berkovitch M, Keresteci A, Koren G. Efficacy of prilocaine lidocaine cream in the treatment of premature ejaculation. J Urol. 1995;154:1360–1.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Mohammed Abu El-Hamd.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Ethical statement

The current study was reviewed and asserted by the ethical and scientific committee, Faculty of Medicine, Sohag University.

Informed consent

Informed consents were taken from patients after compete explanations for the possible benefits and side effects from the current clinical trial.

This clinical trial was registered on the Clinical Trials.gov website (https://clinicaltrials.gov. NCT04062357).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abu El-Hamd, M. Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial. Int J Impot Res 33, 96–101 (2021). https://doi.org/10.1038/s41443-019-0225-9

Download citation

Search

Quick links